Drug Profile
AT 9283
Alternative Names: AT-9283Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astex Therapeutics
- Developer Astex Pharmaceuticals; Astex Therapeutics; Cancer Research UK; National Cancer Institute (Canada)
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Bcr-abl tyrosine kinase inhibitors; Janus kinase-2 inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Medulloblastoma; Multiple myeloma; Myelofibrosis; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 08 Apr 2022 Preclinical pharmacodynamic data presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
- 09 Jan 2013 NCIC Clinical Trials Group completes a phase I trial in solid tumours and non-Hodgkin's lymphoma (second-line therapy or greater, monotherapy) in United Kingdom (NCT00443976)